2012 performance: objectives met
- Sales up 6.8% at constant exchange rates
- €260 million in operating income before non-recurring items
- €134 million in free cash flow
- Robust international expansion, particularly in emerging markets, whose sales grew 17% on an organic basis and represented 29% of consolidated revenue
Reinforced strategic focus on key areas of specialization:
- Clinical microbiology
- Industrial applications
- High medical value immunoassays
- Competitiveness led by innovation, with three major market launches in 2013
Download
- Filename
- pr_biomerieux_resultats_2012_en.pdf
- Size
- 314 KB
- Format
- application/pdf